Acadia Pharmaceuticals posts Q3 2026 revenue of $342 million and raises full‑year outlook
Acadia reported third‑quarter 2026 GAAP revenue of $342 million, a 22% year‑over‑year increase, driven by strong growth in its DAYBUE and NUPLAZID franchises. DAYBUE net sales rose 39% to $140 million and NUPLAZID sales grew 12% to $202 million. Net income fell to $54 million ($0.31 per share). The company lifted its DAYBUE full‑year sales guidance to $505‑$520 million and its total‑year revenue outlook to $1.265‑$1.295 billion.
Why it matters
The higher‑than‑expected sales and the raised guidance suggest continued commercial momentum, which could support the stock price. The company also reported $976 million of cash and investments, providing liquidity for ongoing R&D and potential acquisitions.
Key facts
- 1GAAP total revenues for Q3 2026 were $342 million, up 22% year‑over‑year. sec.gov
- 2DAYBUE GAAP net sales were $140 million, up 39% year‑over‑year. sec.gov
- 3NUPLAZID GAAP net sales were $202 million, up 12% year‑over‑year. sec.gov
- 4Net income for the quarter was $54 million, or $0.31 per diluted share. sec.gov
- 5Full‑year 2026 DAYBUE net sales guidance was raised to $505‑$520 million. sec.gov
- 6Full‑year 2026 total revenue guidance was updated to $1.265‑$1.295 billion. sec.gov
Open questions
- Material 2 reports Q3 revenue of $420.8 million, which conflicts with the $342 million GAAP figure reported in materials 3, 4 and 5.
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.